Company news: CSL Behring and McGraw-Hill

Share this article:
CSL Behring awarded advocacy grants worth around $100,000 to six patient groups through its Local Empowerment for Advocacy Development program, which supports groups helping patients using plasma-derived or recombinant therapies for rare and serious diseases, including bleeding disorders, immune deficiencies and hereditary angioedema.

McGraw-Hill launched mobile versions of its AccessMedicine and AccessPharmacy sites for healthcare professionals. The publisher currently supports iPhone and iPhone 3G, Android and BlackBerry Bold.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.